CS
DRMA icon

Clear Street’s Dermata Therapeutics DRMA Stock Holding History

Clear Street’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,000
Closed -$39.4K – 1123
2025
Q4 		$39.4K Buy
+17,000
New +$55.5K ﹤0.01% 650

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Clear Street's DRMA Position: Q1 2026 in Review

Clear Street sold out of Dermata Therapeutics (DRMA) in Q1 2026, closing a stake of 17,000 shares — an estimated $39.4K sold.

Clear Street first reported a position in DRMA in Q4 2025 and held it in 1 quarter. The position peaked at $39.4K in Q4 2025. 7 funds tracked by Wall St. Rank hold DRMA as of Q1 2026.

  • Clear Street reported no remaining Dermata Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Clear Street sold 17,000 Dermata Therapeutics shares in Q1 2026, an estimated $39.4K.
  • Clear Street first reported a position in Dermata Therapeutics in Q4 2025 and held it in 1 quarter.
  • Clear Street's Dermata Therapeutics position peaked at $39.4K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2026.

Based on Clear Street's 13F filing for Q1 2026, filed 15 May 2026.